Phathom Pharmaceuticals (PHAT) Gains from Sales and Divestitures (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has 5 years of Gains from Sales and Divestitures data on file, last reported at $154077.0 in Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $154077.0, down 69.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $154077.0 (down 69.7% YoY), and the FY2025 annual result was $1.5 million, up 53.5% from the prior year.
• Gains from Sales and Divestitures fell to $154077.0 in Q1 2026 per PHAT's latest filing, from $1.5 million in the prior quarter.
• Over five years, Gains from Sales and Divestitures peaked at $1.5 million in Q4 2025 and troughed at $102453.0 in Q4 2022.
• A 5-year average of $631010.2 and a median of $428558.0 in 2023 frame the typical range for Gains from Sales and Divestitures.
• The sharpest annual moves came in 2023 and 2026: Gains from Sales and Divestitures surged 885.77% in 2023, then sank 69.7% in 2026.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $102453.0 in 2022, then surged by 885.77% to $1.0 million in 2023, then retreated by 4.36% to $965881.0 in 2024, then jumped by 53.5% to $1.5 million in 2025, then sank by 89.61% to $154077.0 in 2026.
• Business Quant data shows PHAT's Gains from Sales and Divestitures at $154077.0 in Q1 2026, $1.5 million in Q4 2025, and $1.3 million in Q3 2025.